The White House delayed the public launch of TrumpRx, the administration’s direct‑to‑consumer drug marketplace, after administration officials and outside counsel flagged potential anti‑kickback and compliance risks. HHS has issued guidance and an Office of Inspector General bulletin outlining safeguards for manufacturers — including avoiding billing federal payers and ensuring independent prescribers — but launch timing remains unclear. Pharma heavyweights including Pfizer, AstraZeneca and Sanofi had already signed on to provide discounted lists on the platform. Observers say legal and operational limits—chiefly the anti‑kickback statute and concerns about conditioned pricing or promotion—are the likely reasons for the pause. Health Secretary Robert F. Kennedy Jr. suggested a near‑term launch window, but sources told press outlets the event was postponed while legal teams iron out risk mitigation. The delay matters for manufacturers planning commercial and patient‑access strategies linked to TrumpRx, and it could reshape how companies price and distribute selected medicines if access through the platform ultimately proceeds under strict regulatory guardrails.